Kamel Khalili, Excision BioTherapeutics
FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV
The FDA has cleared a company trying to use CRISPR gene-editing to cure HIV to begin clinical trials.
The study, run by the startup Excision BioTherapeutics, will likely begin early next year, CMO Lisa Danzig said, after final details are hashed out. It will involve three groups of three healthy HIV patients, with each group given a sequentially higher dose as the company tests the safety of the new therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
